Clinical Trials Browser

Completed × Interventional × Antibodies, Bispecific × Clear all

NCT05101109 2024-07-31

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT03030287 2020-09-03

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00467506 2011-11-11

RIT in MTC

Phase 2 Completed

Thyroid Neoplasms